Panoramic: Automotive and Mobility 2025
Yu-An Chang (Shanghai IP Agency)
Counsel Intellectual Property
Languages
English, Mandarin, Taiwanese
Yu-An's practice spans the full spectrum of intellectual property law. He advises on licensing, technology transfers, joint ventures, and strategic collaborations, as well as commercial arrangements that help clients expand into new markets and fields. He has guided companies on IP aspects of mergers and acquisitions, IPOs, financing, investments, and restructuring projects where intellectual property was a critical asset.
On the contentious side, Yu-An represents global brands in trademark, copyright, and patent enforcement, developing practical strategies that protect IP rights and reinforce market position.
Yu-An’s work has supported clients in consumer goods, retail, education, technology, pharmaceuticals, medical devices, chemicals, and energy industries where innovation and intellectual property protection are essential to growth.
Advised a multinational pharmaceutical company on acquisition and licensing of a novel clinical-stage bispecific antibody with Chinese partners, enabling multi-jurisdictional development
Advised a multinational conglomerate on structuring IP and technology licensing and transfer arrangements with Chinese partners to manufacture commercial and industrial energy storage systems
Advised a leading international toy company on trademark, copyright and patent protection, enforcement, and licensing strategies in China
Advised a global medical device company in an IP and technology collaboration with a Chinese partner to develop advanced surgical navigation systems
Advised a international conglomerate on IP and technology licensing arrangements with a Chinese partner for production and distribution of high-performance chemicals across Asia Pacific
Advising international companies on IP aspects of technology-driven mergers and acquisitions, restructurings, and investments in China
Advising international brands in China on IP protection, enforcement and portfolio management strategies to safeguard innovation and strengthen market position
Advising multinational pharmaceutical companies on licensing and collaboration arrangements with Chinese biotech firms